<code id='3E6DE00276'></code><style id='3E6DE00276'></style>
      • <acronym id='3E6DE00276'></acronym>
      <center id='3E6DE00276'><center id='3E6DE00276'><tfoot id='3E6DE00276'></tfoot></center><abbr id='3E6DE00276'><dir id='3E6DE00276'><tfoot id='3E6DE00276'></tfoot><noframes id='3E6DE00276'>
      • <optgroup id='3E6DE00276'><strike id='3E6DE00276'><sup id='3E6DE00276'></sup></strike><code id='3E6DE00276'></code></optgroup>
        5. <b id='3E6DE00276'><label id='3E6DE00276'><select id='3E6DE00276'><dt id='3E6DE00276'><span id='3E6DE00276'></span></dt></select></label></b><u id='3E6DE00276'></u>
          <i id='3E6DE00276'><strike id='3E6DE00276'><tt id='3E6DE00276'><pre id='3E6DE00276'></pre></tt></strike></i>
          
    
          
      
          
       
      
          
        
      
          
      
          
        
          
          
          
            
          
            
          
              
          
                
          hotspot 
          
                
          
                
          
              
          
            
          
            
            
          
          
          
       
        
          
      
          
      
          
        
          
        
          
          
            
          
                           
          hotspot  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      Page View：4
                                  
                                    
          
                                    
          Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC.
          Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. 																									Michelle C. Gevint for STAT
          NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?
          Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.
          advertisement
          Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Physicians aren't 'burning out.' They're suffering from moral injury
                                
                            
          Next article：  
                                      
                                          At least 13 dead in Texas as scorching temps continue
                                                                    
          
            
          
           
            
          
          
          
       
          
        
          
        
      
          
      
          
                                                
        
          leisure time
          
                  
          

                    
          
            
          
              
                Wildfire smoke exposes gaps in outdoor worker protections
                
          
                        
              
          
                Wildfire smoke exposes gaps in outdoor worker protections
                
          
                  
          ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?
                
          
                        
              
          
                Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?
                
          
                  
          1:03JackSmith,thentheDepartmentofJustice'schiefofthePublicIntegritySection,posesforphotoattheDepartm
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                In age of alternative facts, a scholarly course on calling out crap
                
          
                        
              
          
                In age of alternative facts, a scholarly course on calling out crap
                
          
                  
          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
         
        
          
          
        
          

          
          
            
          
          
          
            
          Flint parents haunted by uncertainty, fears of lead poisoning
          
            
          ElizabethTrambleworriesabouthowtheleadinFlint'sdrinkingwaterwillaffectherchildren.FabrizioCostantini
          
          
          
          
          
            read more